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Over the past few years antidiabetic agents have contributed significantly to the total drug expenditure. The increased prevalence 
of type 2 diabetes and market entry of new and more expensive antidiabetic agents have led to increases in the diabetes drug 
expenditure. On the other hand, several cost containment policies have been implemented over the years to curb the increasing 
expenditures. The aim of this study is to decompose and quantify the increase in the diabetes drug expenditure in Finland between 
2003 and 2015. Understanding the specific cost dynamics underlying the total diabetes drug expenditure is important for 
policymakers. 
 
All reimbursed outpatient diabetes drug purchases in Finland between 2003 and 2015 were extracted from the national 
Prescription Register, which is maintained by the Social Insurance Institution of Finland (Kela). Purchases of antidiabetic agents 
were identified from the register based on the Anatomical Therapeutic Chemical (ATC) classification system. Using Fisher’s ideal 
indexes, the change in the per capita diabetes drug expenditure was decomposed into six different determinants: 
(1) purchase volume; (2) purchase size; (3) therapeutic choices between drug classes; (4) drug choices between different active 
ingredients; (5) unit costs; and (6) changes between packages. The decomposition was conducted separately for insulins and non-
insulin antidiabetic drugs.  
 
From 2003 to 2015, the per capita diabetes drug expenditure increased by10.38 euros for insulins and by 14.83 euros for non-
insulins. The expenditure growth for insulins was mainly driven by volume effects: the increase of the number of purchases 
increased the per capita expenditure by €4.30 and the increase in the size of purchases by €3.98. Changes in therapeutic choices 
increased the per capita expenditure by €3.74. For non-insulins, the main components of the expenditure increase were changes 
in therapeutic choices and changes in purchase volume, which increased the per capita expenditure by €9.59 and €9.48, 
respectively. Changes in purchase size increased the non-insulin per capita expenditure by €1.38. Price effects, measured as 
changes in cost per Defined Daily Dose (DDD), as well as changes in product mix, i.e. substitutions between different packages 
within the same active ingredient, had decreasing effects on the expenditure of both insulins and non-insulins. For insulins, the 
decreasing effect of price changes was €0.95, and the substitutions to cheaper alternatives at the package level decreased the 
expenditure by €1.07. For non-insulins, the decreases were €4.18 and €0.97, respectively. 
 
For both insulins and non-insulins, the main component of the expenditure increase were volume effects. The increase expenditure 
resulting from increases in volume effects is likely explained by the increased incidence of type 2 diabetes. The increased 
incidence of type 2 diabetes is also reflected in the consumption of insulins since as the disease progresses type 2 diabetes is also 
treated with insulin. Therapeutic choices from older to newer drugs and more expensive drugs have increased expenditures in both 
drug classes. Given the impact of therapeutic choices on drug expenditure, further research is required to ensure that investments 
in the use of newer drugs result in proportionate improvements in treatment outcomes. Price effects had a decreasing effect on 
expenditures, but their impact was modest in comparison to increases from other components.  
 
In conclusion, the main determinants of expenditure increase are similar for both insulins and non-insulins. However, the relative 
impact of the determinants varied between them. Therefore, from the cost containment perspective, different policy measures may 
be considered. For insulins, due to their relatively high unit cost, the introduction and uptake of biosimilar products is a key 
measure to influence expenditure growth. For non-insulins, concentrating on the non-price components of the drug expenditure is 
encouraged. 
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Diabeteslääkkeiden osuus lääkkeiden kokonaiskustannuksista on viimeisten vuosien aikana kasvanut merkittävästi. Erityisesti 
tyypin 2 diabetes yleistyy niin Suomessa, kuin muissakin länsimaissa. Potilasmäärän kasvu sekä uusien, entistä kalliimpien 
lääkkeiden markkinoille tulo, ovat johtaneet diabeteslääkkeiden kustannusten kasvuun. Toisaalta sääntelyllä ollaan pyritty 
vaikuttamaan lääkkeiden hinnoitteluun. Tutkielman tavoite on selvittää tarkemmin diabeteslääkkeiden kustannusten kasvun 
taustalla olevia tekijöitä, sekä eri tekijöiden suhteellista osuutta kokonaiskustannuksiin Suomessa vuosien 2003 ja 2015 välillä. 
Tutkielman tulokset laajentavat aikaisempaa tietämystä diabeteslääkkeiden kokonaiskustannusten taustallaolevasta dynamiikasta, 
sillä vastaavaa analyysiä ei ole Suomessa aikaisemmin tehty. 
 
Tutkielman aineisto poimittiin Kansaneläkelaitoksen (KELA) ylläpitämästä reseptilääkerekisteristä. Lopullinen tutkimusaineisto on 
kokonaisaineisto, joka kattaa kaikki Suomen apteekeista tehdyt diabeteslääkeostot vuosien 2003 ja 2015 välillä. Aineistoon 
sovelletaan Fisherin indeksihajotelmaa, jonka avulla diabeteslääkkeiden kokonaiskustannusten kasvu on mahdollista jakaa 
kuuteen eri kustannuskomponenttiin: (1) ostokertojen määrä; (2) yhdellä ostokerralla ostettujen lääkkeiden määrä; (3) muutokset 
lääkkeiden käytössä eri lääkeaineryhmien välillä; (4) muutokset lääkkeiden käytössä eri lääkeaineiden välillä; (5) muutokset 
yksikkökustannuksissa; ja (6) muutokset käytössä samaa lääkeainetta sisältävien pakkausten välillä. Indeksihajotelma tehdään 
erikseen insuliineille ja muille diabeteslääkkeille pois lukien insuliineille, joita käytetään pääasiassa tyypin 2 diabeteksen hoidossa. 
 
Tulokset osoittavat, että insuliinien kokonaiskustannukset kasvoivat vuosien 2003 ja 2015 välillä asukasta kohti 10,38 eurolla 
ja tyypin 2 diabeteslääkkeiden kokonaiskustannukset 14,83 eurolla. Merkittävimmät tekijät insuliinien kustannusten kasvun 
taustalla olivat muutokset lääkkeiden käytön määrässä: muutokset ostokertojen määrässä kasvattivat kustannuksia 4,30 eurolla 
asukasta kohti ja yhdellä ostokerralla ostettujen lääkkeiden määrän kasvu 3,98 eurolla. Lisäksi, uusien lääkeaineryhmien 
käyttöönotto on kasvattanut insuliinien kustannuksia 3,74 eurolla. Tyypin 2 diabeteslääkkeille uudempien lääkeaineryhmien 
käyttäjäosuuksien kasvu johti 9,59 euron nousuun kustannuksissa asukasta kohti. Muutokset ostokertojen määrässä kasvattivat 
kustannuksia 9,48 eurolla asukasta kohti ja yhdellä ostokerralla ostettujen lääkkeiden määrän kasvu 1,38 eurolla. Laskevat 
yksikkökustannukset ja halvempien pakkausvaihtoehtojen saatavuus ovat puolestaan laskeneet kustannuksia sekä insuliineille että 
tyypin 2 diabeteslääkkeille. Insuliinien kustannukset asukasta kohti laskivat 0,95 euroa yksikkökustannusten laskun johdosta ja 
1,07 euroa halvempien pakkausvaihtoehtojen käytön johdosta. Tyypin 2 diabeteslääkkeille kustannukset laskivat vastaavasti 4,18 
euroa yksikkökustannusten laskun ja 0,97 halvempien pakkausvaihtoehtojen johdosta. 
 
Molempien insuliinien sekä tyypin 2 diabeteslääkkeiden kustannusten kasvun taustalla olivat muutokset ostokertojen määrässä ja 
yhdellä ostokerralla ostettujen lääkkeiden määrässä. Lääkkeiden käytön määrän kautta tuleva kustannusten kasvu selittyy pitkälti 
potilasmäärän kasvulla. Tyypin 2 diabeteksen yleistyminen heijastuu todennäköisesti myös insuliinien kulutukseen, sillä taudin 
edetessä 2 tyypin diabetesta hoidetaan myös insuliinilla. Lisäksi uusien ja kalliimpien lääkkeiden käyttöönotolla on ollut selkeä 
vaikutus kustannusten kasvuun. Uusien lääkkeiden käytöstä saatuja hyötyjä on syytä tutkia tarkemmin, jotta voidaan varmistua, 
että uusien lääkkeiden käytöstä saavutetut hyödyt ylittävät niiden käytöstä koituvat kustannukset. Yksikkökustannusten lasku ja 
edullisempien pakkausvaihtoehtojen saatavuus ovat laskeneet kustannuksia molemmissa lääkeryhmissä. Yksikkökustannuksista 
ja halvemmista pakkausvaihtoehdoista saatu säästö on kuitenkin suuruusluokaltaan pieni verrattuna muihin 
kustannuskomponentteihin ja näin ollen kokonaiskustannukset ovat kasvaneet.  
 
Johtopäätöksenä voidaan todeta, että sekä insuliinien että muiden diabeteslääkkeiden kustannusten kasvun taustalla on samat 
tekijät, mutta yksittäisen tekijän vaikutus kokonaiskustannuksiin eroaa näiden kahden lääkeryhmän välillä suuresti. Tämän 
perusteella esitän, että jatkossa tulisi harkita lääkeryhmäkohtaisia toimenpiteitä kustannusten hillitsemiseksi. Insuliinien 
yksikkökustannukset ovat keskimäärin korkeammat kuin muilla diabeteslääkkeillä, joten rinnakkaisvalmisteiden laajempi 
käyttöönotto todennäköisesti kiihdyttäisi hintakilpailua insuliinimarkkinoilla joka voisi johtaa säästöihin. Muiden diabeteslääkkeiden 
kuin insuliinien kohdalla on kustannusten hillitsemisen kannalta syytä tarkastella muihin kuin hintakomponentteihin kohdistuvia 
toimenpiteitä. 
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1 Introduction
Today, pharmaceuticals play a vital role in the health care system. Globally, pharma-
ceuticals represent the third largest expenditure item of expenditure on health, after
inpatient and outpatient care. In Finland, like in most other developed countries
drug expenditure has increased faster than the gross domestic product (GDP) and
total expenditure on health between 2000 and 2014. The growing drug expenditure
reflects the increase in demand for drugs to treat aging population and chronic dis-
eases as well as the introduction of new and more expensive drugs. In most countries
public spending is used to finance significant part of prescription pharmaceutical
consumption. Due to the central role of pharmaceuticals in the health care system,
the policy makers face the following trade off in terms of controlling the pharmaceu-
tical expenditure: on one hand they need to ensure that the patients have access and
can afford the appropriate treatment. On the other hand the policy makers need to
provide the environment and incentives for pharmaceuticals companies to research
and develop new drugs. (OECD 2015 & 2017)
The expenditures have been increasing in many drug groups but both globally
and especially in Finland antidiabetic agents have been among the most used phar-
maceuticals and as such contributed significantly to the increase in pharmaceutical
expenditure. The consumption of antidiabetics has almost doubled in Organization
for Economic Co-Operation and Development (OECD) countries during the 2000s.
This increase in the consumption of antidiabetic agents, is to a large extent explained
by the rising prevalence of diabetes. Globally, it is estimated that currently 415 mil-
lion adults have diabetes and by 2040 this will rise to 642 million. In Finland with
population of approximately 5.4 million people, there are about 50,000 people with
type 1 diabetes and about 250,000 people with type 2 diabetes. Additionally, it
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is estimated that there are roughly 150,000 undiagnosed cases of type 2 diabetes.
Based on recent forecasts it estimated that the number of diabetes patients could
double during the next 10 to 15 years. (OECD 2015, IDF 2016, Diabetes: Current
Care Guidelines Abstract 2016)
The current 9% prevalence of diabetes in Finland is roughly at the EU and
OECD average. However, despite the average level of prevalence, the consumption
of antidiabetic agents is the highest in Finland of all OECD countries. While drugs
account only for a part of the total treatment cost of diabetes, the sales of antidiabetic
agents have quadrupled during the 2000s in Finland. The increase in sales translates
into increases in drug expenditure and since 2003 the share of drugs used in diabetes
of the total reimbursed drug expenditure has increased from 5% (49 million euros) to
11% (148 million euros) in 2015. At this rate the antidiabetic agents are also among
the most commonly used drugs in Finland. In 2015, three drugs used in diabetes
were on the top ten list of most sold medical products and when looking at the
drugs with highest reimbursement costs, three drugs used in diabetes were on top
five. (IDF 2016, OECD 2015 & 2017, Fimea 2015, Pharma Industry Finland 2016,
Ruskoaho 2016)
The gloomy forecasts regarding the development of the prevalence rates of di-
abetes suggest that the role of diabetes becomes even more important in terms of
public drug spending in the future. This creates a need for the healthcare sector
and policy makers to understand the specific determinants driving the increase in
diabetes drug expenditure and ensure that the allocation of resources to pharmaceu-
ticals provide value. Thus, the purpose of this thesis is to decompose and quantify
the increase in Finnish diabetes drug expenditure between 2003 and 2015. Using
index theoretical methods and a product level register covering essentially the entire
sales data of antidiabetic agents in Finland, the change in per capita diabetes drug
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expenditure between 2003 and 2015 is decomposed into six different determinants:
(1) purchase volume; (2) purchase size; (3) therapeutic choices between drug classes;
(4) drug choices between different active ingredients; (5) unit costs; and (6) changes
between packages within the same active ingredient. The decomposition is done
separately for insulins and non-insulin antidiabetic agents.
The results indicate that the main components of expenditure increase, for both
insulins and non-insulins, have been increases in purchase volume, purchase size
and changes in therapeutic choices between drug classes. Unit costs and changes
between packages had decreasing effect on the expenditure in both drug classes, but
their impact was modest compared to other determinants. Furthermore, the relative
impact of the determinants varied between insulins and non-insulins.
2 Background
In this section I briefly discuss key concepts that are important in order to grasp
the rest of the thesis. First subsection briefly describes diabetes as a disease. The
following subsections 2.2 and 2.3 introduce the Anatomical Therapeutic Chemical
system, which is a standardized classification system for drugs and Defined Daily
Dose (DDD), which is the commonly unit used to measure pharmaceutical con-
sumption. Section 2.4 discusses the special characteristics of the pharmaceutical
industry as well as the nature of competition in the pharmaceutical market. Section
2.5 describes the role of national health insurance, reimbursement schemes and cost
containment policies on pharmaceuticals in general as well as in Finland.
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2.1 Brief introduction of diabetes
Diabetes is a chronic disease that can be divided in two main types; type 1 and type
2. Type 1 Diabetes is usually diagnosed in children and young adults. In type 1
diabetes the pancreas is unable to produce insulin and therefore the main treatment
for type 1 diabetes are insulin injections. Type 2 diabetes is the more common type
of diabetes. In type 2 diabetes the body is not able to handle insulin properly. At
first, the pancreas makes extra insulin i.e. overcompensates insulin production. But
over time the pancreas is not able to keep up with the insulin production and thus
the blood glucose will drop below normal levels. (Diabetes: Current Care Guidelines
2016).
Unlike people with type 1 diabetes, who require insulin, people with type 2 dia-
betes can initially manage their condition by healthy life style and without pharmaco-
logical intervention. However, once the disease progresses there is an inevitable need
for multiple pharmacotherapies including non-insulin antidiabetic agets, insulins or
both (Finnish Diabetes Association).
2.2 Anatomical Therapeutic Chemical classification system
Anatomical Therapeutic Chemical (ATC) classification system is maintained by the
World Health Organization Collaboration Centre (WHOCC) and divides pharmaceu-
ticals into different, mutually exclusive, groups based on the organ or system which
they are designed to act and their therapeutic, pharmacological and chemical prop-
erties. In the ATC classification system pharmaceuticals are divided into 14 main
groups (1st level) and further into four different levels within each main group. The
2nd and 3rd level are therapeutic and pharmacological sub levels, 4th level identifies
the pharmacological, chemical or the therapeutic group to which the drug belongs.
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The 5th and the final level identifies the active ingredient/chemical substance or the
combination of active ingredients. Products and packages sharing the same 5th level
ATC-code contain the same active ingredient but may differ in the number of units
and strength. (WHOCC 2016)
Drugs used in diabetes are separated as a single group of pharmaceuticals at the
second level of the ATC classification system. At the third level of ATC classification
system antidiabetic agents are further divided into insulins and other blood glucose
lowering drugs, excluding insulins. In this thesis I will refer to these two groups
of drugs as insulins and non-insulins, respectively. The complete classification of
metformin, presented in table 1, illustrates the structure of the ATC-code. In this
thesis the ATC system is used to identify the drugs used in diabetes. Furthermore
the different levels of ATC-system are used as aggregation levels for the index de-
compostion, which is discussed in detail in the Methods section. A complete list of
drugs used in this study and their paths in the ATC hierarchy can be found in the
appendix 1.
Table 1: Anatomic Therapeutic Chemical (ATC) classification system
ATC-code Description
A Alimentary tract and metabolism (1st level, anatomical main group)
A10 Drugs used in diabetes (2nd level, therapeutic subgroup)
A10B Blood glucose lowering drugs, excl. insulins (3rd level, pharmacological subgroup)
A10BA Biguanides (4th level, chemical subgroup)
A10BA02 Metformin (5th level, chemical substance)
Source: WHOCC 2016
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2.3 Defined Daily Dose
The concept of defined daily dose (DDD) was developed for drug consumption statis-
tics and it also maintained by the WHOCC. The basic definition of DDD is the fol-
lowing: ”The DDD is the assumed average maintenance dose per day for a drug used
for its main indication in adults” (WHOCC 2016). DDDs are assigned to each active
ingredient defined by the 5th level of the ATC classification system, for example the
DDD of metformin is 2000 mg. It should be noted that DDD is purely statistical
measure and does not necessarily reflect the average prescribed dose of a given drug.
However, the DDDs provide a fixed unit of measurement independent of price and
dosage form enabling the assessment of trends in drug consumption and aggregations
within and across ATC classification (WHOCC 2016). A complete list of drugs used
in this study and their paths in the ATC hierarchy and the respective DDDs can be
found in the appendix.
2.4 Competition in the pharmaceutical market
The life cycle of a new active ingredient can roughly be divided into three phases.
First phase is the Research and Developement (R&D) phase that precedes the market
entry of the drug. The length of the first phase is on average ten years. After
receiving the marketing authorization begins the second phase, in which the drug is
sold on the market and it is protected by patents and possibly by other intellectual
property rights (IPR). Due to the patent protection the product has potential to
earn monopoly profits during the second phase. The third and final phase begins
when the patent of the chemical substance expires and as a result of generic products
enter the market products entering the market the price competition intensifies and
the monopoly ceases to exist. (Appelt 2010)
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Figure 1: Life Cycle of a pharmaceutical product from patent protection to generic entry.
Source: Appelt 2010
While new products have patent protection and monopoly power during the sec-
ond phase of the life cycle, they may face competition from different products/chemical
compounds that are used to achieve the same therapeutic goal, these are so called
me-too drugs (DiMasi 2004). Within EU, a drug, which is still under patent protec-
tion, may also face competition from parallel imports. Parallel imports are imports
of patented or trademarked product from a country where it is sold by the patent or
trademark holder at a lower price than in the target country (Heath 1999). Thus, the
point of parallel trade is to exploit the price difference between the two countries by
some other company than the marketing authorization holder (Ganslandt & Maskus
2001).
In general, totally synthesized pharmaceuticals have relatively low marginal cost
of production after they have been discovered. This results in fierce competition after
the patent of a drug expires and generic products enter the market (Hurley 2010).
Generic manufacturers have relatively low cost to enter the market since they do not
7
have to undertake R&D to develop new drugs. Instead, generic manufacturers con-
duct bioequivalence tests in order to prove that they are comparable to the patented
product in terms of safety and efficacy. The costs of bioequivalence testing are not
however comparable with the R&D cost of bringing a new product into the market
(Appelt 2010).
The competition between biopharmaceuticals, which are pharmaceuticals that are
extracted from biological sources, is more complex. Two different biopharmaceuticals
cannot be identical in the same sense as two totally synthesized pharmaceuticals
can, because of this biopharmaceuticals are affected with even stricter regulation as
well as higher production costs (Rader 2008). As a result biopharmaceuticals do
not face similar generic or in this case biosimilar competition as totally synthesized
pharmaceuticals (Greene & Riggs 2015). This is important since from drugs used in
diabetes, insulins are biopharmaceuticals
2.5 Reimbursement of pharmaceutical products
A prerequisite for a product to enter in the pharmaceutical market is to gain market
authorization. In Europe the market authorization can cover the whole European
union (EU), in which case the authorization is granted by the European Commission.
However, usually a prerequisite for a prescription drug to receive large scale demand is
an inclusion in the reimbursement scheme of the National Health Insurance (NHI).
Although a drug can enter the market with the market authorization granted by
the European commission, the reimbursement schemes for pharmaceuticals are in
general national and the decision regarding the inclusion of given product in the
reimbursement scheme are made nationally. (Martikainen 2012)
In Finland, the prescription pharmaceutical market is highly regulated. Before
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a drug can enter the reimbursement scheme in Finland, a wholesale price must be
approved by the Pharmaceuticals Pricing Board (Hila), which is appointed by the
Ministry of Social Affairs and Health. In outpatient setting, the retail price of a
reimbursable prescription drug consists of the wholesale price, regulated pharmacy
margin and value added tax (10%) (Fimea 2015). Before the price of a drug is
approved by the pricing board, the drug remains non-reimbursed and the purchase
of these drugs are paid in full by the patient. In 2015, the national health insurance
covered 67% of prescription drug expenditures and over 95% of the diabetes drug
expenditure (Fimea 2015).
The rate of reimbursement depends on the reimbursement category to which
the drug belongs. There are three categories and they are differentiated by disease
severity and an annual ceiling on out-of-pocket costs. In 2015, the basic rate of
reimbursement, which applies to all reimbursable drugs, was 35% (patient pays 65%)
and the annual ceiling was 612.62, after which a fixed 1.50 fee per prescription item
applied. Patients with certain severe or chronic diseases are eligible for higher special
rates of reimbursement (65% or 100%). For 100% reimbursed drugs a fixed fee of
3 euros applies per purchase for maximum of 3 months’ supply of a drug. Insulins
and non-insulins, in general, to the higher special refund category, where the rate of
reimbursement is 100%.
Many countries have implemented several cost containment policies in order to
control for the rising pharmaceutical expenditures. In general these cost contain-
ment policies have focused on the pricing of pharmaceuticals. In Finland, generic
substitution was introduced in 2003, which was followed by the introduction of the
reference price system in 2009. Under the generic substitution system the dispensing
pharmacy is required to offer the customer the cheapest alternative product contain-
ing the same active ingredient, dosage and form as the prescribed product. Both the
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prescribing physician and patient can reject the substitution without affecting the
reimbursement rate of the product. Under the reference price system, a reference
price will be assigned for different pharmaceutical products. The reference price is
then the highest price that will be reimbursed by the NHI. The customer can substi-
tute the prescribed product to the reference priced product within the same product
category. Alternatively, the customer may not substitute the prescribed product to
the reference priced product and if the price of the prescribed product is higher than
the reference price the customer will pay the difference and the NHI will reimburse
the cost up to the reference price. Both the generic substitution and reference price
systems are designed to intensify the price competition between the original and
generic products. (KELA 2017)
There has also been direct price regulations on drugs covered by the National
Health insurance during the study period. First one was in the beginning of 2006
when the wholesale prices were reduced by 5% and the second price regulation took
place in the beginning of 2013 when the wholesale prices of products that were
outside the generic substitution and reference price system were reduced again by
5% (Martikainen et al 2013).
In terms of antidiabetic agents insulins are not affected by the generic substitution
or the reference price system. Recall from section 2.4 that insulins are biopharma-
ceuticals, which means that overall there is less competing or generic products in
the insulin market. Furthermore, it is likely that an insulin user prefers to use the
same product long periods, since she may have dispensing devices (e.g insulin pumps
or injection pens) that are only compatible with a specific brand or product. Thus
substitution between two different products is more complex for insulins than it is
for non-insulins. Non-insulins are affected by both generic substitution and reference
price system. Finally, the wholesale price reductions in 2006 and 2013 have affected
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both insulins and non-insulins.
3 Literature review
In the following subsection I provide an overview of earlier drug expenditure de-
composition studies, these studies present the methods that are used in the analy-
sis of increasing drug expenditures. Furthermore these studies have identified the
main components underlying the increasing drug expenditure. The second subsec-
tion presents few papers that have specifically focused on the economic evaluation
of pharmaceuticals used for treating diabetes.
3.1 Drug expenditure
A number of studies have examined the factors leading to the growing expenditures of
prescription drugs in recent decades. Merlis (2000) provides a review of four studies
explaining the growth in prescription drug spending in the United States during
1990s. He lists three basic reasons because of which the per capita prescription drug
spending may increase over time for a given population:
• Volume: The proportion of the population receiving any prescription grows.
• Unit price: The price of a unit for a particular drug increases.
• Therapeutic choices: Drugs used within the population and the changes be-
tween newer and older generations of drugs
Merlis also emphasizes that the units of measure that are used in drug expenditure
studies have a major impact on the estimates. If utilization is defined in terms of
average number of prescriptions per patient, all the studies find that rising cost per
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prescription was more important factor than utilization change. However, this is
because the price measure includes changes in days’ supply and strength, as well as
in the mix of drugs used. When days, instead of prescriptions are used as units, the
volume measure utilization becomes the more important factor in spending change.
Gerdtham & Lundin (2004) study the increase in drug spending in Sweden during
the 1990s using data on drug deliveries from wholesalers to pharmacies. They use a
model where the drug spending is decomposed to account for changes in quantities,
prices and drug treatment patterns, which they call the residual effect. They find
that real drug spending increased 119% during the study period from 1990 to 2000.
The main driver for the cost increase was the increase in the residual i.e switching
from older to newer drugs. They estimate that the costs would have increased about
31% had there not been changes in the prescribing patterns. The second driver for
growth was the increase in quantity of drugs consumed, they argue that main factor
increasing the quantity is more likely the fact that patients already using drugs receive
more intense treatment in terms of strength and number of units rather than larger
number of people starting treatments. Interestingly, the real prices decreased during
their study period and they also note that there were major differences between
different drug classes in terms of spending growth.
Morgan (2002) studies the determinants of prescription drug expenditure infla-
tion for a population of Canadian seniors using data from British Columbia. He has
developed an analytic framework that accounts for changes in the pattern of exposure
to drugs across therapeutic categories, the mix of drugs used within the therapeu-
tic categories, the rate of generic product selection and the prices of the products.
Findings of this study suggest that all other factors, than the rate of generic product
selection, have caused spending per capita to increase, at least in the subpopulation
of seniors. He emphasizes that change in the mix of drugs across therapies and mix
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of drugs within therapies accounted for over a half of the expenditure increases. The
author also notes that to the extent that, the increase in use of generic products has
decreased the costs of drugs, the policies providing incentives for generic substitution
have been successful in controlling the cost increases.
Morgan (2004) extends his own model presented in Morgan (2002) to account for
determinants in three broad determinants: price effects, quantity effects and thera-
peutic choices, which are then each divided into two sub determinants to further de-
compose the change in per capita expenditure into six separate cost drivers. Morgan
applies his model to all orally administered prescription drugs in Canadian market
from 1998 to 2002. He finds that the volume and mix of drugs across therapeutic
categories are the major factor attributing for cost growth. Additionally, changes in
drug mix within the therapeutic categories, prescription size and prices had increas-
ing effect on the drug spending. Similarly, as in the previous study increase in the
use of generic products has decreased the spending on drugs in Canada.
Morgan’s papers (2002) and (2004) employ index theoretical methods that are
based on Fisher’s ideal indexes. To a large extent this thesis will utilize a similar
model in explaining the cost increase and its determinants for diabetes drugs in
Finland. These methods are presented in greater detail in the Methods section of
this paper.
A couple of more recent studies from South Korea have used similar methods
as the papers described above. Kwon et al. (2015) extend the model proposed by
Gerdtham and Lundin (2004) to better capture and separate the impacts of existing
and entering drugs. They find that during their study period from 2006 to 2010
the overall pharmaceutical expenditure increased by 43% and again the residual
effect was the main factor contributing to the cost growth followed by the quantity
increase. Interestingly, the South Korean study finds that although the prices for
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existing drugs decreased during the study period, existing rather than entering drugs
had a substantial effect on expenditure growth.
A paper by Jo et al. (2016) uses the same model as Morgan (2002) for the study
period from 2008 to 2012 in South Korea. Similarly, as with the results from Canada
major part of the drug expenditure increase in South Korea was attributable to
changes in drugs used across therapeutic categories and within therapeutic categories.
However, they also note that the increases in prices had much smaller effect on overall
expenditures in South Korea than in Canada.
Finally, a couple of papers have focused on the cost growth of specific groups of
pharmaceuticals. Koskinen et al. (2009) studied the cost growth of antipsychotics
and antidepressants in Finland between 1999 and 2005. They found that the main
sources of cost growth differed between these two groups of pharmaceuticals. For
antipsychotics the main source of cost growth was therapeutic choices from cheaper
to more expensive drugs. Whereas the cost increase for antidepressants was mainly
driven by the increase in the number of users. Wu et al. (2013) focused on anti-
infective drug expenditure in Tianjin China between 2003 and 2007 they find that
both increase in the number of users as well as changes in therapeutic choices from
older to newer and more expensive drugs were the main cost drivers. Additionally
they find that price effect had a negative effect on expenditures, while the generic
substitution had positive effect on the expenditures implying that original product
are chosen over the generic alternatives within drugs containing the same active
ingredient.
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3.2 Diabetes specific
Rathmann et. al (2007) uses data from 1994-2004 to compare the prescription drug
costs of diabetic patients to a age and gender matched control group in Germany.
They find that mean annual total cost per diabetic patient went up from 372e in 1994
to 559e in 2004, whereas among non-diabetic patients the costs increased only from
147e to 210e respectively. They note that different types of diabetes medication
has different impact on the costs of diabetes medication. The main cost factor was
insulin, which accounted for 22% of total drug costs in diabetic patients in 2004.
All oral anti-diabetic drugs accounted for 8% of total costs in 2004. Additionally,
drugs that were newer at the time of the study (glitatzones, glinides and insulins),
accounted for 15% of total costs among diabetic patients in 2004.
Gordon et al. (2013) have conducted a literature review based cost effectiveness
evaluation considering the insulin use in treating type 2 diabetes in United Kingdom.
They compare the use and cost effectiveness of the intermediate acting human iso-
phane insulin to the more expensive long acting analog insulins. The authors stress
the importance of the distinction between direct and indirect costs by concluding
that although the diabetes-related medication expenditure is, in general, lower in
users of human insulin compared to users of long-acting insulin analogs, overall the
use of long acting analog insulins may have cost decreasing effect. The authors argue
that the use of long acting analog insulin results in fewer complications stemming
from low blood sugar (hypoglycemia) and thus offsetting the cost difference between
the two types of insulins.
Ahuja & Chou (2016) have conducted a literature review where they concentrate
on the usage trends and comparative effectiveness of newer medications used for
treating type 2 diabetes. They focus on comparing treatments from four different
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chemical subgroups. They note that the usage trends of products from these different
chemical subgroups follow, to a large extent, the known efficacy and safety profile
of these drugs. However, they conclude that despite providing expansion in the
therapeutic selection for treating patients with diabetes, given their novelty, their
costs and benefits have not yet been fully established. Thus, utilization of these
newer drugs in diabetes treatment has also created difficulties for policy makers to
create guidelines for choosing optimal treatment.
Finally, Ja¨rvinen et al. (2016) have compared use of diabetic medication and clin-
ical guidelines between Norway, Denmark, Sweden and Finland. Interestingly, this
paper concludes that in 2013 the most common first-line treatment in all four coun-
tries was metformin, but for second-line treatment Danish, Swedish and Norwegian
guidelines suggest sulfonylureas, whereas the Finnish guideline suggest dipeptidyl
peptidase 4 (DPP-4) inhibitors. On the face of it DPP-4 inhibitors have been more
expensive compared to sulfonylureas. They argue that this difference in the treat-
ment guidelines can be partly due to the fact that the Finnish guideline does not take
a stand on the economic aspects of diabetes treatment. The authors also note that
there are differences on the recommended initial insulin type for patients with type
2 diabetes between the four countries. In comparison to the findings in the paper
by Gordon et al. (2013) the Norwegian and Swedish guidelines suggest intermediate
acting human isophane insulin as the initial insulin type, whereas the Danish and
Finnish guidelines do not present a preferred alternative.
To sum up the research presented above shows that the determinants of the drug
expenditure can differ between countries, study periods and drug groups. Further-
more, the economic evaluations regarding antidiabetic agents emphasize the cost
effect of newer pharmaceuticals as well as differences between national treatment
guidelines between Nordic countries. Against this background it is important that
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the determinants of drug expenditures are identified individually for different drug
groups (e.g. for insulins). Different sources of expenditure increase imply different
policy measures and since the source of expenditure increase may differ substantially
between two different drug classes, it is unlikely that decompositions conducted for
broader categories of drugs give realistic picture about drug group specific determi-
nants of expenditure increase.
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4 Data
The data for this study was extracted from the Finnish Prescription Register main-
tained by The Social Insurance Institution of Finland (SII 2015). The Finnish Pre-
scription Register contains records of all prescription drug purchases reimbursed by
National Health Insurance for all Finnish residents living in non-institutional set-
tings. One observation in the dataset represent a one time purchase of a single
person from a Finnish pharmacy. The data consists of purchases of drugs used in
diabetes between January 1st 2003 and December 31st 2015 and includes information
on the dispensing date of each purchase, Anatomical Therapeutic Chemical (ATC)
classification code of the active substance, product identification code (Nordic article
number, VNR), the number of purchased products and total cost of the purchase.
Purchases of combination products i.e products that contain two active ingredi-
ents were classified into the respective ATC classes based on the individual active
ingredients and DDD amounts were calculated for both active ingredients in the
combination product. The prescription register is merged with SII’s Defined Daily
Dose (DDD) database (SII 2015) using the product identification code. The DDD
database supplements the prescription register with information on strength, package
size and DDD for a given active ingredient in the product. Only chemical substance
used in diabetes that is dropped from the analysis is guar cum, since it does not have
an official DDD amount assigned by the WHOCC. In 2015, the sales of guar cum
were less than 1% of the sales of drugs used to treat diabetes (Fimea 2015). The
final dataset contains over 20 million observations and can be considered to represent
complete sales data of antidiabetic agents in Finland between 2003 and 2015.
The costs used are total costs of the purchase, containing both the NHI’s reim-
bursement part, patient’s own contributions as well as value added tax. Cost per
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DDD of the purchase is used as the unit cost and is calculated using the formula
below.
((
Cost
Quantity
)/Strength) ∗DDD ∗ no. of purchased packages = Price per DDD
The costs of purchases of combination products of non-insulin antidiabetic agents
are allocated entirely to that active ingredient in the combination product which had
higher unit cost as an individual active ingredient in the given year. For example,
the cost of a product containing both metformin and sitagliptin is allocated entirely
to the sitagliptin, since sitagliptin’s unit cost is higher than that of metformin. Con-
sequently, the metformin DDDs from the combination product are considered as
having zero cost. While this chosen procedure will cause some bias in the cost esti-
mation, it allows to keep all euros and DDDs in the data. Thus, given that the use
of combination product is very common in Finland, excluding them completely from
the analysis would have resulted in much larger bias. Finally, the Finnish population
grew by 265 653 individuals during the study period (Statistics Finland 2015). In
order to negate effect of population growth all costs are treated as cost per capita.
Finally, there have been new products entering the market and older products
exiting the market during the study period. For entering products the observed entry
cost is projected back to 2003 and, for exiting products the exit cost is projected
forward to 2015. This extension of the price series assures that there is no jump in
price upon entry. Furthermore, this way all products will have price data for every
period in a way that affects neither the average price nor the total value of the market
at a given year.
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5 Theoretical framework
There are at least two important reasons why pharmaceutical expenditures should
be analyzed carefully. The first reason is that the expenditure on pharmaceuticals
has opportunity costs and it is possible that an alternative allocation of resources
could have produced more health. The second reason is that the resources available
for pharmaceutical expenditures are limited. If the expenditures increase to a high
enough level, it may jeopardize the provision of pharmaceuticals to those in need at
a reasonable cost. Therefore policy makers need to be able to identify the correct
source of the expenditure increase in order to asses that the increases in expenditure
are justified. Conversely, they need to be able to apply the correct cost containment
policies to those components that create increases in the expenditure that are not
cost effective. (Hurley 2010)
A simple starting point for such analysis would be to separate the increase in
expenditure to a quantity component and a price component. If the expenditure
increase is driven by the quantity component one would be interested if the increase in
the amount of drug used stems from an increased medical need among the population.
If this is the case then ensuring access to appropriate and cost effective drug therapy
through the NHI may be reasonable use of public resources. Limiting access to drug
therapy through NHI could result in savings in the drug expenditure but in turn
increase costs in other health care sectors. (Morgan 2002)
If the expenditure is driven by the price component one would control the ex-
penditures by controlling prices. It is obvious that that the cost of one unit of
pharmaceuticals has a direct impact on the drug expenditure. However, there is
more than one dimension to the price component of pharmaceutical expenditure.
For example, in this two component setting the shift in use from older and cheaper
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drugs towards newer, more expensive and perhaps more novel drugs would be cap-
tured by some abstract and underlying trend in the price and quantity components.
As a result this kind of decomposition into ”pure” price and quantity components
has little or no use as a decision making tool. (Berndt et al 2000; Morgan 2002)
When analyzing the determinants of increasing drug expenditure it is especially
interesting to separate the increasing effect resulting from unit prices and use of newer
products. If the price effect can be separated from the effect resulting from changes
therapeutic choices, it is possible to evaluate whether investments in to newer prod-
ucts are cost effective in the sense that they result in proportionate improvements in
treatment outcomes. This is rather important since standard economic theory sug-
gests that higher cost implies higher quality, otherwise the rational consumer would
not buy them. However, if we think about the market for prescription drugs where
the consumer consumes the drugs, but does neither prescribe nor usually pay the full
price for them. Then there are the physicians who prescribe the drugs but do neither
consume nor pay for them. Finally, there is the government who pays for the drugs
through the NHI but does neither prescribe nor consume them. Outside this triangle
there are also pharmaceutical companies developing new products with the goal of
maximizing profits. Due to the asymmetric information, imperfect decision making
and non standard financial incentives the market for pharmaceuticals is inconsistent
with the inference of standard economic models. Thus, it is likely that there is not
automatically a straight forward relationship between the relative price and relative
value. (Morgan 2002)
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6 Methods
In this thesis I use index-theoretical methods to analyze and decompose the changes
in diabetes drug expenditure. An index number is a standardized measure that
decomposes value aggregates V =
∑n
i=1 piqi into price and quantity components
for item i at some aggregation level and is calculated at regular intervals, years for
example.
A price index can be calculated as a weighted average of the ratio of prices
between the base period 0 and the current period t. Correspondingly, a quantity
index can be calculated as a weighted average of the ratio of quantities between the
base period 0 and the current period t. In general, price and quantity indexes give
different weights to different items i at a given aggregation level. The difference
between many index numbers is in the weights, which they use. The indexes used in
this thesis take the form of Fisher’s Ideal Index, which is the geometric average of
Laspeyres’ and Paasche’s indexes. (Eurostat 2016)
6.1 Laspeyres’ and Paasche’s indexes
Laspeyres’ price indexes use base period 0 weights and it is calculated by multiplying
item i’s price p in the current period t by good i’s base period quantity q0 the sum
of the products ptq0 for all items i is then divided by the sum of the products of
prices and quantities in the base period. Put differently, the total expenditure in the
current period at a given level of aggregation with base period quantities is divided
by the total expenditure in the base period. Laspeyres’ quantity index is analogously
defined. The term pi0qi0∑n
i=1 pi0qi0
is the weight term and it is representing the good i share
of the total expenditure in the base period. We can see that Laspeyres quantity index
uses the base period prices as weights whereas the Laspeyres’ price index uses the
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base period quantities as weights.
Laspeyres′ price index =
n∑
i=1
(
pit
pi0
)
pi0qi0∑n
i=1 pi0qi0
=
∑n
i=1 pitqi0∑n
i=1 pi0qi0
Laspeyres′ quantity index =
n∑
i=1
(
qit
qi0
)
pi0qi0∑n
i=1 pi0qi0
=
∑n
i=1 pi0qit∑n
i=1 pi0qi0
Paasche price index uses current period weights and it is calculated by multi-
plying the the price of good i in the current period t with the quantity of good i
in the current period t. The sum of these products is the divided by the sum of
the products, which are calculated by multiplying the base period 0 price with the
current period t quantities. The term pitqit∑n
i=1 pitqit
is representing the item i share of the
total expenditure in the current period. We can see that Paasche’s quantity index
uses the current period prices as weights, whereas the Paasche’s price index uses the
current period quantities as weights.
Paasche′s price index =
(
n∑
i=1
(
pit
pi0
)−1
pitqit∑n
i=1 pitqit
)−1
=
∑n
i=1 pitqit∑n
i=1 pi0qit
Paasche′s quantity index =
(
n∑
i=1
(
qit
qi0
)−1
pitqit∑n
i=1 pitqit
)−1
=
∑n
i=1 pitqit∑n
i=1 pitqi0
Based on the economic theory firm’s optimize their behavior such that they will
maximize profits. Laspeyres’ and Paasche’s indexes fail to fully capture this optimiz-
ing behavior of firms in every time period, since their weights are fixed into the base
and current periods, respectively (Fissel 2014). The take away is that Laspeyres’
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index and Paasche’s index bound the true economic activity. Whether Laspeyres’ or
paasche’s index is the upper bound depends on the market. Laspeyre’s index tend to
put more weight on the older products and Paasche’s tend to put more weight on the
newer products. In a price taking market, where quanities consumed go up as prices
go down, Laspeyre’s index tend to be the upper bound. In a market, where firms
are able to set prices and substitute output towards goods that are relatively more
expensive to existing ones, Paasche’s index tend to be the upper bound (Eurostat
2016). In general the gap between the upper bound and lower bound tend to increase
as the distance between the base period and current period increases. Therefore an
average of the two bounding indexes can provide a more accurate estimate of the
true state of the market.
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6.2 Fisher’s ideal index & factor reversal test
The Fisher index is calcualted by taking the geometric mean of Laspeyres’ and
Paasche’s indexes for prices or quantities. Since, Fisher’s index is an average of
the two indexes that bound the true economic activity, it provides a higher order
approximation of the theoretical true economic index, which would be an exact
representation of the true economic activity. (Fissel 2014; Diewert 1993)
Fisher′s price index =
√√√√ ∑ni=1 pitpi0 pi0qi0∑ni=1 pi0qi0∑n
i=1
(
pit
pi0
)−1 pitqit∑n
i=1 pitqit
=
√∑n
i=1 pitqi0∑n
i=1 pi0qi0
∗
∑n
i=1 pitqit∑n
i=1 pi0qit
Fisher′s quantity index =
√√√√ ∑ni=1 qitqi0 pi0qi0∑ni=1 pi0qi0∑n
i=1
(
qit
qi0
)−1 pitqit∑n
i=1 pitqit
=
√∑n
i=1 pi0qit∑n
i=1 pi0qi0
∗
∑n
i=1 pitqit∑n
i=1 pitqi0
Furthermore, the Fisher index satisfies the factor reversal test, hence the name
ideal, which checks that the product of price index and quantity index equals the
expenditure ratio between the current and base period. This is a desirable fea-
ture from methodological perspective, since passing the factor reversal test ensures
consistency between price indexes, quantity indexes and expenditure (Diewert 1993).
Factor reversal test
If (Pt0) ∗ If (Qt0) =
∑
ptqt∑
p0q0
=
Vt
V0
= Expenditure Ratio
where If (Pt0) is a Fisher price index and I
f (Qt0) is a Fisher quantity index
25
Finally, indexes are descriptive and do not imply causality. The strength of in-
dexes is that they allow to compare relative changes in prices and quantities between
two time periods. However, it would be wrong to conclude that for example change
in the price of insulin A ”caused” the price change of all insulins. What we can say
is that the price change between insulin A and the price change of all insulins are
related, since Insulin A constitutes a significant share of the total insulin market.
(Fissel 2014)
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6.3 Index construction
Similarly to Morgan (2002 & 2004) I use the Fisher ideal index decomposition method
to asses the different factors explaining the increase in per capita expenditure on
diabetes drugs between 2003 and 2015. Using the register-based data I decompose the
change in per capita expenditure into six different determinants that fall into changes
in three upper level categories: volume effects, price effects and therapeutic choices.
Fisher’s index is used since it satisfies the factor reversal test and therefore the
product of the six determinants will exactly equal the current year over base year per
capita expenditure ratio (Fisher 1925 and Diewert 1993). The decomposition utilizes
different levels of the ATC classification system (Figure 2) and is done separately for
insulins and non-insulins, ATC classes A10A and A10B respectively.
Recall from section 2.2 that the ATC classification system divides the active
ingredients into mutually exclusive categories. From this follows that each active
ingredient used in antidiabetic agents belongs to only one item at each level of the
ATC system. As a result the total value of the market is the same at all levels
of the ATC system. I have supplemented the ATC system with the package level,
where the same logic applies: every package containing the same active ingredient in
the same form and the same number of units of equal strength belong to a unique
package number. I calculate a Fisher index for each level of the ATC system as well
as for the package level. From these indexes and their ratios I am able to extract
the six determinants of the expenditure increase: (1) purchase volume; (2) purchase
size; (3) therapeutic choices between drug classes; (4) drug choices between different
active ingredients; (5) unit costs; and (6) changes between packages within the same
active ingredient.
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(a) ATC hierarchy of insulins (b) ATC hierarchy of non-insulins
Package level boxes indicate the total number of unique packages, varying in quantity of
units, strength per unit and form, during the study period.
Figure 2: Anatomical Therapeutic Chemical hierarchies of insulins and non-insulins
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6.3.1 Quantity effects
Quantity effects are result of changes in the number of purchases and changes in the
size, measured in DDDs, of those purchases. Changes in the number of purchases is
captured by constructing a quantity index with expenditure data aggregated at the
3rd level of the ATC classification system.
∆PurchaseV olume =
√∑
C0atc3Q
t
atc3∑
C0atc3Q
0
atc3
∗
∑
Ctatc3Q
t
atc3∑
Ctatc3Q
0
atc3
The effect of changes in purchase size is measured as the expenditure weighted
average of changes in the number of DDDs (U) per purchase (R) at the 5th level of
the ATC system (Morgan 2004). It is important to take into account the changes
in purchase size, since trends in purchase size could have an effect on the purchase
volume. For example, larger quantity and/or stronger units of the drug per purchase
could reduce the amount of purchases. An advantage of using DDDs as units is that
it captures the changes in both strength and quantity.
∆PurchaseSize
=
√∑
Ctatc5RQ
0
atc5R∑
C0atc5RQ
0
atc5R
∗
∑
Ctatc5RQ
t
atc5R∑
C0atc5RQ
t
atc5R
/√∑
Ctatc5UQ
0
atc5U∑
C0atc5UQ
0
atc5U
∗
∑
Ctatc5UQ
t
atc5U∑
C0atc5UQ
t
atc5U
The share of quantity effects attributing for the total change in per capita ex-
penditures is the product of the changes in prescription volume and prescription
size.
∆Quantity effects = ∆PurchaseV olume ∗∆PurchaseSize
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6.3.2 Therapeutic choices
Therapeutic choices influence drug expenditure through changes in the type of antidi-
abetic agents purchased (Morgan 2004). In my analysis therapeutic choices capture
the changes in expenditures at the 3rd level of the ATC classification system that are
results of changes in market shares at the 4th level of the ATC classification system.
∆TherapeuticMix
=
√∑
Ctatc3RQ
0
atc3R∑
C0atc3RQ
0
atc3R
∗
∑
Ctatc3RQ
t
atc3R∑
C0atc3RQ
t
atc3R
/√∑
Ctatc4RQ
0
atc4R∑
C0atc4RQ
0
atc4R
∗
∑
Ctatc4RQ
t
atc4R∑
C0atc4RQ
t
atc4R
Working down the ATC hierarchy the drug mix is defined as the changes in
expenditures at the 4th level of the ATC resulting from changes in market shares at
the active ingredient (5th) level of the ATC system. For example, if the relatively
more expensive dipeptyl peptidase 4 (DPP-4) inhibitors captures market share from
less expensive thiazolidinediones, it would result as an increase in the therapeutic
mix. Changes in the market shares between two different types of thiazolidinediones
would be, in turn, reflected as a change in the drug mix.
∆DrugMix
=
√∑
Ctatc4RQ
0
atc4R∑
C0atc4RQ
0
atc4R
∗
∑
Ctatc4RQ
t
atc4R∑
C0atc4RQ
t
atc4R
/√∑
Ctatc5RQ
0
atc5R∑
C0atc5RQ
0
atc5R
∗
∑
Ctatc5RQ
t
atc5R∑
C0atc5RQ
t
atc5R
The share of therapeutic choices attributing for the total change in per capita
expenditures is the product of the changes in therapeutic mix and and drug mix.
∆Therapeutic choices = ∆TherapeuticMix ∗∆DrugMix
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6.3.3 Price effects
Price effects are factors that directly affect the cost of drugs. Price effects contain
the changes in the price charged for products on the market and changes in the
average unit cost stemming from substitution between different products within the
same 5th level ATC code (Morgan 2004). Price changes are measured with a price
index aggregated at the package level measuring the change in cost per DDD for all
products.
∆Price changes =
√∑
CtpackUQ
0
packU∑
C0packUQ
0
packU
∗
∑
CtpackUQ
t
packU∑
C0packUQ
t
packU
The product mix measures the impact of substitutions between packages within the
same active ingredient. These changes can be a result of increasing use of generic
products as well as relatively low-cost alternatives from the original manufacturer.
Product mix is measured with an expenditure weighted average of changes in unit
cost at the 5th level of ATC system explained by changes in the market shares at
the package level.
∆Product mix
=
√∑
Ctatc5UQ
0
atc5U∑
C0atc5UQ
0
atc5U
∗
∑
Ctatc5UQ
t
atc5U∑
C0atc5UQ
t
atc5U
/√∑
CtpackUQ
0
packU∑
C0packUQ
0
packU
∗
∑
CtpackUQ
t
packU∑
C0packUQ
t
packU
The share of price effects attributing for the total change in per capita expendi-
tures is the product of the changes in price changes and product mix.
∆Price effects = ∆PriceChanges ∗∆ProductMix
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6.3.4 Expenditure per capita
Finally, the total change in per capita expenditure between the base and current
period is equal to the product of the three broad categories or equivalently product
of the six narrower determinants of drug expenditures. A demonstration that the
decomposed index measuring the change in expenditure per capita satisfies the factor
reversal test can be found in the appendix 2.
∆Expenditure per capita = ∆Price effects ∗∆Therapeutic choices ∗∆ Quantity effects
6.4 The euro values of determinants
To make the interpretation of the index decomposition easier I convert the index
values to euro values, following the procedure described in Morgan (2004). The
indexes resulting from the Fisher ideal index decomposition will all have value of one
in the base year. Following from the factor reversal test the expenditure ratio between
the current period and base period will equal the product of the six determinants.
Taking the natural logarithm will transform the base period value to of the indexes
equal to zero. Also, as a resutl the multiplicative property of the six determinants
becomes additive. As a result the natural logarithm of the current period over base
period expenditure ratio will equal the sum of the natural logarithms of the six
determinant indexes:
ln(
expendituret
expenditure0
) =
N∑
i=1
ln(indexi,t)
where: i ∈ {PurchaseV olume, PurchaseSize, TherapeuticMix, DrugMix, PriceChanges, ProductMix}
From this follows that the percentage change in euros between the base period and
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the current period resulting from a given determinant can be estimated by dividing
the the natural logarithm of a given determinant index by the natural logarithm
of the current year over the base year expenditure ratio. The sum of the ratios of
the natural logarithm of each determinant index over the natural logarithm of the
current period over base period expenditure ratios is then equal to one.
N∑
i=1
1
ln( expendituret
expenditure0
)
∗ ln(indexi,t) = 1
The euro value of a given determinant is then equal to this ratio multiplied by
the difference of the expenditures between the current period and the base period.
1
ln( expendituretexpenditure0 )
∗ ln(indexi,t)∗ (expendituret − expenditure0) = euro value of determinanti,t
Tables containing the index values, the natural logarithms of the index values
and the euro values of the determinants for both insulins and non-insulins can be
found in the appendix 3.
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7 Results
From 2003 through 2015, the yearly number of insulin purchases increased from 397
550 to 555 778 (39%) purchases per year, while the per capita expenditure of insulins
increased from 8.33 euros to 18.71 euros (124%) (Table 2). The number of purchases
of non-insulins increased from 643 945 to 1 512 249 (135%) purchases per year, while
their per capita expenditure increased from 5.29 euros to 20.12 (280%) euros (Table
4). The increases in per capita expenditures translate into increases of 59 million
and 83 million in total expenditures for insulins and non-insulins, respectively.
The total amount of annually purchased DDDs increased during the study period
for insulins from approximately 35 million DDDs to 61million (73%) (Table 2) and
for non-insulins from approximately 67 million DDDs to 126 million DDDs (86%)
(Table 4). Despite the increase in the total amount of DDDs, the average yearly
DDD amount per non-insulin user decreased from 500 DDDs in 2003 to 415 DDDs
(-17%) in 2015 (Table 5). For insulins the average yearly DDD amount per insulin
user increased from 461 DDDs in 2003 to 505 DDDs (10%) in 2015 (Table 4). The
average cost per DDD increased in both drug classes; from 1.23 euros in 2003 to 1.67
euros (36%) in 2015 for insulins and from 0.41 euros in 2003 to 0.88 euros (115%) in
2015 for non-insulins.
When comparing the changes in prevalence of insulin users and non-insulin users
from 2003 to 2015, there was a modest increase in the prevalence of insulin users,
1.48% vs 2.22% (Table 3), while the increase in the prevalence of non-insulin users
was larger, 2.59% vs. 5.53% (Table 5).
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Table 2: Costs and quantities of insulins
Year Number of DDDs Total cost in euros Cost per capita (e) Number of purchases
2003 35, 383, 481 43, 384, 576 8.33 397, 500
2004 36, 591, 161 51, 028, 476 9.78 398, 715
2005 38, 494, 353 55, 799, 228 10.66 403, 895
2006 40, 451, 831 57, 843, 811 11.01 411, 834
2007 44, 644, 257 66, 878, 341 12.67 439, 331
2008 49, 164, 145 78, 297, 429 14.77 469, 644
2009 52, 809, 150 88, 306, 042 16.58 488, 518
2010 55, 950, 369 97, 353, 322 18.19 505, 223
2011 57, 482, 217 102, 685, 881 19.10 509, 959
2012 58, 409, 081 104, 723, 123 19.39 514, 677
2013 59, 476, 930 103, 357, 290 19.05 522, 972
2014 60, 287, 943 100, 757, 096 18.48 536, 834
2015 61, 369, 329 102, 374, 902 18.71 555, 778
2015− 2003 25, 985, 849 58, 990, 326 10.38 158, 278
%∆ 2003− 2015 73.44% 135.97% 124.51% 39.82%
Table 3: Per user statistics of insulin users
Year Number of users Prevalence
Average number
of purchases per user
Average number
of DDDs per user
Average cost
per user
2003 76, 833 1.48 % 5.17 460.52 564.66
2004 80, 508 1.54 % 4.95 454.50 633.83
2005 83, 974 1.60 % 4.81 458.41 664.48
2006 87, 085 1.66 % 4.73 464.51 664.22
2007 93, 107 1.76 % 4.72 479.49 718.30
2008 98, 705 1.86 % 4.76 498.09 793.25
2009 103, 605 1.95 % 4.72 509.72 852.33
2010 107, 813 2.01 % 4.69 518.96 902.98
2011 111, 082 2.07 % 4.59 517.48 924.42
2012 113, 876 2.11 % 4.52 512.92 919.62
2013 117, 078 2.16 % 4.47 508.01 882.81
2014 119, 583 2.19 % 4.49 504.15 842.57
2015 121, 615 2.22 % 4.57 504.62 841.80
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Table 4: Costs and quantities of non-insulins
Year Number of DDDs Total cost in euros Cost per capita (e) Number of purchases
2003 67, 258, 856 27, 550, 946 5.29 643, 945
2004 74, 680, 321 31, 205, 201 5.98 703, 042
2005 81, 315, 129 35, 297, 146 6.74 758, 327
2006 85, 486, 403 33, 704, 450 6.41 808, 207
2007 91, 338, 548 36, 288, 278 6.88 879, 602
2008 97, 667, 106 40, 266, 582 7.60 999, 607
2009 100, 707, 304 43, 807, 666 8.22 1, 065, 160
2010 106, 238, 830 57, 243, 296 10.70 1, 129, 280
2011 109, 435, 001 69, 770, 302 12.98 1, 159, 895
2012 113, 211, 303 81, 041, 227 15.00 1, 206, 571
2013 115, 886, 633 88, 154, 169 16.24 1, 255, 267
2014 120, 296, 861 98, 434, 505 18.06 1, 322, 792
2015 125, 674, 277 110, 115, 529 20.12 1, 512, 249
2015− 2003 58, 415, 420 82, 564, 583 14.83 868, 304
%∆ 2003− 2015 86.85% 299.68% 280.28% 134.84%
Table 5: Per user statistics of non-insulin users
Year Number of users Prevalence
Average number
of purchases per user
Average number
of DDDs per user
Average cost
per user
2003 134, 603 2.59 % 4.78 499.68 204.68
2004 147, 124 2.82 % 4.78 507.60 212.10
2005 158, 460 3.03 % 4.79 513.16 222.75
2006 169, 346 3.22 % 4.77 504.80 199.03
2007 188, 504 3.57 % 4.67 484.54 192.51
2008 213, 467 4.03 % 4.68 457.53 188.63
2009 231, 257 4.34 % 4.61 435.48 189.43
2010 247, 752 4.63 % 4.56 428.81 231.05
2011 258, 837 4.82 % 4.48 422.80 269.55
2012 269, 501 4.99 % 4.48 420.08 300.71
2013 281, 814 5.19 % 4.45 411.22 312.81
2014 292, 736 5.37 % 4.52 410.94 336.2
2015 302, 604 5.53 % 5.00 415.31 363.89
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7.1 Decomposition results of insulins
The euro values of the determinants explaining the per capita expenditure increase
for insulins are listed in the figure 3. The largest increase in the per capita ex-
penditures for insulins resulted from changes in purchase volume. The number
of insulin purchases increased by 158 278 purchases (Table 2), which is captured
by the PurchaseV olume index and accounted for 4.30 euros out of the total in-
crease in per capita expenditures (10.83 euros), between 2003 and 2015. The second
largest increase in the per capita expenditures for insulins resulted from changes in
PurchaseSize which measures the expenditure weighted average number of DDDs
per purchase. The changes in PurchaseSize accounted for an increase of 3.98 euros.
Changes in the therapeutic choices had the third largest impact on per capita
expenditures. TherapeuticMix, measuring the cost impact for insulins resulting
from changes in the expenditure shares at the 4th level of the ATC system, accounted
for 3.74 euros in per capita expenditure inflation. Insulins are classified in four
different groups at the 4th level of the ATC system: Fast-acting, intermediate-acting,
mixed and long-acting insulins. Drug mix, measuring the cost impact resulting from
changes in expenditure shares within the four groups classified at the 4th level of the
ATC system, for example, the shift in use from glargine insulin to detemir insulin,
which are both long acting insulins is captured by the DrugMix. DrugMix had a
modest but increasing effect on the per capita expenditure accounting for an increase
of 0.38 euros in per capita expenditures, between 2003 and 2015.
Price effects including changes in unit costs measured by PriceChanges index
and changes in package changes within the same active ingredient measured by
ProductMix index had a decreasing effect on per capita expenditures. PriceChanges,
measuring the changes in cost per DDD for insulin products, indicates that the per
37
capita expenditure was 0.95 euros less than it would have been if the unit costs re-
mained at 2003 levels. Changes in ProductMix, measuring the impact of shifting
towards cheaper (or more expensive) products within the same active ingredient,
accounted for a decrease of 1.07 euros in per capita expenditures, between 2003 and
2015.
7.2 Decomposition results of non-insulins
The euro values of the determinants explaining the per capita expenditure increase
for non-insulins are listed in the figure 3. The largest increase in per the capita
expenditures of non-insulins resulted from changes in the TherapeuticMix, which
accounted for an increase of 9.59 euros. The number of non-insulin purchases in-
creased by 868 304 purchases between 2003 and 2015. This change captured by the
PurchaseV olume resulted as the second largest increase accounting for 9.48 euros
out of the total change in per capita expenditure (14.83 euros). The change in the
PurchaseSize increased the per capita expenditure by 1.38 euros.
Differing from insulins the DrugMix decreased the per capita expenditure of
non-insulins by 0.47 euros. Changes in PriceChanges had decreasing effect on per
capita expenditures. The decreasing trend in cost per DDD translates to a decrease
of 4.18 euros in expenditures per capita, between 2003 and 2015. The changes in
ProductMix decreased per capita expenditures by 0.97 euros.
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(a) Decomposition results 2003-2015
Note: The scale of y-axis is different for insulins and non-insulins
(b) Euro values of determinants in 2015
Figure 3: Decomposition results for insulins and non-insulins
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7.3 Validity of the decomposition
In the spirit of the discussion in the theoretical framework section, here I will provide
”naive decompositions” into price and quantity components at a single aggregation
level to further motivate the need to decompose the expenditure into several com-
ponents. Given the framework outlined in this methodology section, in terms of
decomposing the expenditure increase into just price and quantity components, I
have two options. The first is to take the PurchaseV olume index as the quantity
index and by construction the rest of the change in expenditures that is not mea-
sured by this quantity index would be measured by the price index at the same level
of aggregation, in this case changes in average cost per capita per purchase. This
would be the purchase level decomposition The second option is to take the price
index defined at the package level i.e. the PriceChanges as the price index. Again,
the rest of the changes in expenditures that is not captured by the package level
price index would be captured by the package level quantity index. This would be
the unit level decomposition. The results of the naive decompositions are illustrated
in table 6.
Purchase level
∆Expenditure per capita
=
√∑
C0atc3Q
t
atc3∑
C0atc3Q
0
atc3
∗
∑
Ctatc3Q
t
atc3∑
Ctatc3Q
0
atc3
∗
√∑
Ctatc3Q
0
atc3∑
C0atc3Q
0
atc3
∗
∑
Ctatc3Q
t
atc3∑
C0atc3Q
t
atc3
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Unit level
∆Expenditure per capita
=
√∑
C0packUQ
t
packU∑
C0packUQ
0
packU
∗
∑
CtpackUQ
t
packU∑
CtpackUQ
0
packU
∗
√∑
CtpackUQ
0
packU∑
C0packUQ
0
packU
∗
∑
CtpackUQ
t
packU∑
C0packUQ
t
packU
Table 6: Results of price and quantity decompositions of insulins and non insulins
Level Component Insulin Non-insulin
Purchase level
Quantity 4.30 e 9.48 e
Price 6.08 e 5.35 e
Total change 2015 - 2003 10.38 e 14.83 e
Unit level
Quantity 11.33 e 19.01 e
Price −0.95 e −4.18 e
Total change 2015 - 2003 10.38 e 14.83 e
The results of the naive decomposition are quite mixed. At the purchase level we
can argue that quantity component quite accurately captures the the cost impact of
the increase in the purchase volume. However, the price component shows substantial
contribution to the expenditure increase. Given the regulated nature of the Finnish
drug market it would be hard to argue that this increase is resulting from pure
price inflation. At the unit level the effect of changes in the price component gives
more credible results in terms of price changes, but now the impact of the mixture
of all other cost drivers is in the quantity component. The naive decomposition
results illustrate the troubles of determining the specific cost dynamics underlying
the expenditure increase, by just single price and quantity component decomposition.
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7.4 Relationship between Laspeyre’s, Paasche’ and Fisher’s
indexes
The left graph in the figure 4 shows the development of the Laspeyres’ Paasche’s and
Fisher’s indexes taken from PriceChanges index for insulins in relation to base year
of 2003. We see that the Laspeyres’ and Paasche’s indexes start to diverge roughly
at the 2006. Recall from section 2.5 that the first wholesale price reduction took
place in 2006. This one time change in prices of insulins most likely amplifies the
divergent effect between the Laspeyre’s and Paasche’s indexes, due to the difference
in their weights. Similarly, between 2012 and 2013, when the second wholesale price
reduction took, place there is a clear increase in the gap between the Laspeyres’ and
Paasche’s indexes. Furthermore, it is noteworthy that here the Laspeyres’ index is
the upper bound. The Laspeyres index essentially calculates what the expenditures
would have been in the base period at the current period costs. From figure 6 (right)
we see that despite the decreasing price index the purchased quantities of all other
insulins than long-acting insulins decreased as well. Thus the weight from base
period quantities underestimates the decrease of the true price index. Conversely,
the Paasches index overestimates the decrease, due to the decrease in prices, since it
takes the market today and compares what expenditure of the current period market
would have been in the base period.
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Figure 4: Relationship between Laspeyre’s, Paasche’ and Fisher’s price indexes of insulins
and non-insulins
The graphs are based on the PriceChanges index of insulins and non-insulins
Note the difference in scales of the y-axes between insulins and non-insulins
The right graph in the figure 4 shows the development of the Laspeyres’ Paasche’s
and Fisher’s indexes taken from PriceChanges index for non-insulins in relation to
base year of 2003. We can see the divergence of Laspeyres’ and Paasche’s indexes
beginning between 2006 and 2009. Here the wholesale price reduction in 2006 has an
impact as well. But more importantly, as we can see from right side graph in figure
7, DPP-4 inhibitors entered the market in 2007. As a result of the market entry of
this new class of products, Paasche’s index is the upper bound for non-insulin index.
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Paasche index checks what the expenditures of the current period market would have
been at the base period costs. As the consumption of the new and relatively more
expensive product increases, Paasche’s index tend to overestimate cost impact of the
new drug class relative to the base year. Compare this to Laspeyres’ price index,
which uses base period quantities as weights. The newer products entering the market
have no consumption in the base year and thus Laspeyres’ index to underestimates
the cost impact.
The graphical analysis of this subsection illustrates the over- and underestimating
nature of Laspeyres’ and Paasche’s indexes. Thus providing further motivation for
the choice of Fisher’s indexes as the analysis tool. However, the graphical analysis
also pinpoints some weaknesses of index methods. These weaknesses include the
sensitivity to changes in market environment as well as the increase in the possible
measurement error of the Fisher’s index resulting from the increasing gap between
the Laspeyres’ and Paasche’s indexes as the distance between the current and base
period gets longer.
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7.5 Discussion
From 2003 to 2015 per capita diabetes drug expenditure increased by 135% for
insulins and by 280% for non-insulins. The main drivers of this expenditure increase
in both drug classes were changes in volume effects and therapeutic choices. Price
effects, however, had a decreasing effect on the diabetes drug expenditure. Despite
the similarities in the broad categories of the expenditure growth, the relative impact
of the determinants varied between the insulins and non-insulins.
Volume effects, the combination of purchase volume and purchase size, was the
main determinant of the per capita expenditure increase for both insulins and non-
insulins. Regarding that the Finnish reimbursement system allows buy no more
than three month’s supply of drugs at one time, the increase in the purchase volume
reflects the increase in the number of people buying diabetes drugs.
The growth in the purchase volume is at least partly explained by the increased
incidence of type 2 diabetes. There are most likely many reason behind the increased
incidence of type 2 diabetes. However, from the Finnish population statistics we see
that the Finnish population ”aged” slightly over the study period. In year 2000
15% of the Finnish population were over 65 years old, whereas in 2016 20.9% of the
Finnish population were over 65 years old (Statistics Finland 2017). Given that old
age is one of the main risk factors for type 2 diabetes (Current Care Guidelines),
this aging of the Finnish population is most likely one significant factor behind the
increase in the volume effects. On the other hand, studies have reported decreasing
trend in age at the time of diagnosis of type 2 diabetes (Amos et al 1997). The
decreasing trend at the time of diagnosis is usually linked to obesity, which is the
main risk factor for type 2 diabetes (Current Care Guide lines). OECD data indicates
that the prevalence of obesity increased in Finland between 2000 and 2013 by 2.3
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percentage points. In 2013 the prevalence of obesity in Finland was 24.8%, while the
OECD average was 19.0% (OECD Health at Glance 2015).
The increasing effect of changes in purchase size on the diabetes drug expendi-
ture indicate that the three-month time equivalent number of DDDs has increased
between 2003 and 2015. However, based on previous studies, the purchase size hav-
ing comparable impact on drug expenditure with volume and therapeutic choices has
been uncommon in other drug groups (e.g. Morgan 2004, Wu et al 2013). The large
impact of purchase size on expenditure change of insulins may reflect the intensified
insulin therapy, which may be required in patients with type 2 diabetes (Swennen et
al, 2009).
The changes in therapeutic choices from old to new and more expensive drugs had
a significant impact on per capita diabetes drug expenditure for both insulins as well
as non-insulins. For insulins the shift has been from the use of intermediate-acting
insulins and mixed insulins towards the use of long-acting insulins, that accounted
for roughly 75% of the total expenditures of all insulins in 2015 (Figure 5).
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Note: the total expenditure of insulins increased by 58,990,326e between 2003 and 2015
Figure 5: Changes in expenditure shares and DDDs of insulins 2003 - 2015
Regarding non-insulins, measured in DDDs metformin is the most used non-
insulin antidiabetic agent and its’ consumption has been increasing steadily. Met-
formin is the recommended first line treatment for type 2 diabetes by the Finnish
clinical guidelines (Current Care Guidelines). However, in terms of expenditure the
share of metformin has been decreasing since 2009. The main contribution to expen-
diture increase has been the shift from the use of sulfonylureas and thiazolidinediones
towards DPP-4 inhibitors. The Finnish clinical guidelines recommend both newer
DPP-4 inhibitors as well as older drugs such as sulfonylureas as the second line
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treatment for type 2 diabetes.
It is also important to take note on the increase in expenditure share of the other
blood glucose lowering drugs, excluding insulins-category, which contains the GLP-
1 analogues that are currently the most recent non-insulin antidiabetic agent that
have entered the market. The expenditure share of this drug category is similar to
that of metformin even though the consumption of metformin, measured in DDDs,
is approximately 12 times higher (Figure 6). This underlines the cost impact of new
products entering the market.
Note: the total expenditure of non-insulins increased by 82,564,583e between 2003 and
2015
Figure 6: Changes in expenditure shares DDDs of non-insulins 2003 - 2015
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The use of newer and more expensive products has been identified as a significant
cost driver in many previous studies (Morgan 2004 Wu et al. 2013, Koskinen et al
2009). Additionally, shifts in utilization towards newer anti diabetic agents, such as
DPP-4 inhibitors have been reported from other countries as well (Christensen et al.
2016). However, there are also significant differences. Based on publicly available
databases the use of DPP-4 inhibitors was approximately five times more common
in Finland than it was in Sweden, Norway or Denmark measured in DDDs/1000 in-
habitants/day (Socialstyrelsen, Medstat, Follkehelseinstituttet 2017). Differing from
other Nordic countries the Finnish clinical guidelines do not take economic aspects in
to account, which may to an extent, explain the differences between the four Nordic
countries (Ja¨rvinen et al. 2016). On the other hand, Finland has put a particular
emphasis on diabetes treatment. During 2000 - 2010 The Development Programme
for the Prevention and Care of Diabetes (DEHKO) was carried out, which may have
also affected to the increase in the use of newer drugs. Although it is unclear and
out of the scope of this study, whether the use of these newer drugs has lead to
improvements in treatment outcomes, OECD data reveals that diabetes related hos-
pital admissions have decreased every year from 2008 to 2013 in Finland (Health
at Glance 2015). To what extent this has been due to the use of newer drugs is
however not obvious and requires further research. In general, given the significant
impact of therapeutic choices on drug expenditure, careful economic evaluations are
required to ensure that investments in the use of newer drugs result in proportionate
improvements in treatment outcomes.
Earlier research has reported both positive (Morgan 2004) and negative effects
(Jo et al. 2016, Koskinen et.al 2009) of prices on drug expenditure. In Finland,
the drug market is highly regulated, and thus increases in prices are in practice
extremely rare. Thus, the observed decreasing effect of prices on drug expenditure
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was expected. However, the price decrease was larger for non-insulins than it was
for insulins. Presumably, the difference in the magnitude of price effects is due to
cost containment policies that have been introduced in Finland. Many non-insulin
antidiabetic agents are subject to the generic substitution and reference price systems
(Fimea, HILA), which may have increased the price competition between products
and steered the purchases toward lower cost alternatives.
The decreasing impact of prices was smaller for insulins. Due to the fact that
insulins are mostly parenterally administered biopharmaceuticals, they do not face
similar price competition as non-insulins (Greene & Riggs 2015). Additionally, the
substitution between different insulin products may be complex due to different dis-
pensing devices, e.g., insulin pumps. Given this framework for competition in the
insulin market, the decreasing price effects are, presumably, the result of the two
direct price regulations, which reduced the wholesale prices of products by 5%, in
2006 and 2013.
The results of this thesis on diabetes drug expenditure agree with previous drug
expenditure decomposition studies in the sense, that volume effects and therapeutic
choices have been the main forces driving the diabetes drug expenditure. Despite
price effects have decreased, the decrease has not been sufficient to curb the total
diabetes drug expenditure. Although, it should be noted that without the decreasing
price effects the expenditures would have increased even more. Furthermore, despite
the growing expenditure, appropriate use of pharmaceuticals even in high volumes
and costs might produce cost savings in other healthcare sectors and gains in length
and quality of life (Han 2005). This emphasizes the need for rational prescribing
policy as well as further research on the cost effectiveness of newer treatments.
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7.5.1 Strengths and Limitations
The strength of this thesis is that I had access to a national register that contains
a complete outpatient sales data on drugs used in diabetes in Finland between 2003
and 2015. Thus, it should be noted that the indexes constructed in this study are
based not on a sample of drugs but on all of them. Guar cum was the only anti
diabetic agent excluded from the analysis. A limitation of this analysis is that the
data do not include information on whether the drugs were purchased for treating
type 1 or type 2 diabetes. Inclusion of this information on the analysis would have
broadened the understanding of diabetes drug expenditure, especially in the insulin
category.
Furthermore, combination products were separated into the respective classes
based on the individual active ingredients. The cost of a given combination product
was entirely allocated to the active ingredient, which had higher unit cost and the
other active ingredient was considered as having zero cost. This procedure might
overestimate the decreasing effect of the price changes for the non-insulins. However,
given that the use of combination products is very common in Finland, excluding
them from the analysis would have resulted in even larger bias. In 2015, 10% of sales
of drugs used in diabetes were oral combination products (Fimea 2015). It is also
noteworthy that DDD is a statistical unit and as such does not represent any actual
prescription amount. For example, the DDD of metformin is 2 grams, but the Finnish
clinical guidelines recommend doses up to 3g/day (Current care Guidelines, Ja¨rvinen
2016). However, DDD is widely accepted and used in drug utilization studies and
therefore best available unit for this study. Finally, I did not have information on
the diabetes drugs administered in hospitals. However the amount of diabetes drugs
administered in hospitals is only approximately 2% of all antidiabetic agents. (Fimea
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2015).
8 Conclusions
The aim of this thesis is to study the determinants of the increasing diabetes drug
expenditure in Finland between 2003 - 2015. During this time period the share of
antidiabetic agents of the overall drug expenditure has increased rapidly. At the
same time several cost containment measures have been implemented to control the
expenditures.
To asses the determinants of the increasing diabetes drug expenditure, all reim-
bursed outpatient diabetes drug purchases from Finnish pharmacies between 2003
and 2015 were extracted from the national prescription register, which is maintained
by the Social Insurance Institution of Finland (KELA). Using Fisher ideal index
decomposition method the change in the per capita diabetes drug expenditure is de-
composed into six different determinants: (1) purchase volume; (2) purchase size; (3)
therapeutic choices between drug classes; (4) drug choices between different active
ingredients; (5) unit costs; and (6) changes between packages within the same active
ingredient. The decomposition was done separately for insulins and non-insulins.
For both insulins and non-insulins the largest increases in expenditures resulted
from increases in purchase volume and purchase size. These increases in the amount
of drugs consumed are likely to be explained by the increase in the number of patients.
Also, the increasing prevalence of type 2 diabetes is likely to be reflected in the
consumption of insulin, since as the disease progresses the type 2 diabetes is also
treated with insulin. Additionally, changes in therapeutic choices from older to
newer drugs has contributed significantly to the expenditure increases in both drug
classes. Decreasing unit costs and changes between packages within the same active
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ingredient have resulted in cost savings for both insulins and non-insulins, but the
decreasing impact was modest in comparison to increases from other components.
In this thesis I have calculated specific euro values for the determinants underlying
the increasing diabetes drug expenditure. However, the pharmaceutical expenditures
are only part of the total costs of diabetes and therefore further health economic
evaluations are required in order to investigate the benefit side of these determinant.
Especially, the benefits of using newer drugs should be further explored in order to
ensure that the benefits of using newer drugs exceed the costs of their use.
In conclusion it can be stated that the main determinants of the expenditure
increase are similar for both insulins and non-insulins. However, the impact of a
specific determinant varied substantially between these two drug classes. Therefore
from pure cost containment perspective different policy measures can be considered,
while keeping in mind the limitations of drawing strong conclusion regarding policy
implications from such analysis that lacks the benefit side assessment. For insulins
due to their relative high unit costs, the introduction of biosimilar products is a key
measure to influence the expenditure growth. For non-insulins, concentrating on
the non-price components of the drug expenditure is encouraged. However, the cost
containment policies should not jeopardize the access to appropriate drug treatment,
which is designed to ensure a good quality of life and prevent complications associated
with diabetes. Guaranteeing access to cost-effective drug treatment might result in
savings in total health care costs, since complications and hospitalizations are the
main reason for high total cost of diabetes care (DEHKO, Current Care Guidelines).
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Appendix 1
Anatomical Therapeutic Chemical classification codes &
Defined Daily Doses of insulins and non-insulins
Insulins
60
Non-insulins
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Appendix 2
Factror Reversal test
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∆Expenditure per capita
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Appendix 3
Index values of insulins
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Purchase Volume 1 1.003 1.016 1.036 1.105 1.181 1.229 1.271 1.283 1.295 1.316 1.351 1.398
Purchase Size 1 1.068 1.125 1.170 1.215 1.281 1.336 1.376 1.401 1.411 1.398 1.385 1.363
Therapeutic Mix 1 1.056 1.072 1.089 1.124 1.176 1.223 1.265 1.297 1.318 1.335 1.342 1.339
Drug Mix 1 1.023 1.029 1.039 1.054 1.048 1.048 1.046 1.043 1.036 1.042 1.030 1.030
Price Changes 1 1.010 1.008 0.978 0.970 0.969 0.968 0.968 0.969 0.962 0.940 0.922 0.929
Product Mix 1 1.002 1.006 0.985 0.985 0.981 0.976 0.974 0.973 0.969 0.951 0.931 0.919
Expenditure per Capita 1 1.173 1.279 1.321 1.521 1.773 1.989 2.183 2.292 2.327 2.286 2.218 2.245
The expenditure per capita in a given year is the product of the six determinants in the same year
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Natural logarithms of the index values of insulins
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Purchase Volume 0 0.003 0.016 0.035 0.100 0.167 0.206 0.240 0.249 0.258 0.274 0.300 0.335
Purchase Size 0 0.066 0.118 0.157 0.195 0.247 0.290 0.319 0.337 0.344 0.335 0.326 0.310
Therapeutic Mix 0 0.055 0.070 0.085 0.117 0.162 0.202 0.235 0.260 0.276 0.289 0.294 0.292
Drug Mix 0 0.023 0.028 0.038 0.053 0.047 0.047 0.045 0.042 0.035 0.041 0.030 0.030
Price Changes 0 0.010 0.008 -0.022 -0.031 -0.032 -0.033 -0.032 -0.031 -0.038 -0.062 -0.081 -0.074
Product Mix 0 0.002 0.006 -0.015 -0.015 -0.019 -0.024 -0.026 -0.028 -0.031 -0.051 -0.072 -0.084
Expenditure per Capita 0 0.160 0.246 0.278 0.419 0.572 0.688 0.781 0.830 0.844 0.827 0.797 0.809
The expenditure per capita in a given year is the sum of the six determinants in the same year
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Index values of non-insulins
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Purchase Volume 1 1.092 1.178 1.255 1.366 1.552 1.654 1.754 1.801 1.874 1.949 2.054 2.348
Purchase Size 1 1.036 1.105 1.143 1.167 1.145 1.149 1.205 1.254 1.229 1.243 1.216 1.132
Therapeutic Mix 1 1.011 1.071 1.173 1.270 1.382 1.462 1.679 1.861 2.021 2.156 2.262 2.372
Drug Mix 1 1.011 1.018 1.004 0.987 0.961 0.947 0.942 0.949 0.974 0.952 0.964 0.959
Price Changes 1 0.989 0.926 0.769 0.712 0.649 0.629 0.650 0.667 0.680 0.679 0.683 0.686
Product Mix 1 0.987 0.970 0.933 0.913 0.937 0.939 0.931 0.922 0.919 0.910 0.917 0.917
Expenditure per Capita 1 1.130 1.274 1.212 1.299 1.436 1.554 2.021 2.453 2.835 3.070 3.412 3.803
The expenditure per capita in a given year is the product of the six determinants in the same year
Natural logarithms of the index values of non-insulins
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Purchase Volume 0 0.088 0.164 0.227 0.312 0.440 0.503 0.562 0.588 0.628 0.667 0.720 0.854
Purchase Size 0 0.036 0.099 0.133 0.155 0.135 0.139 0.186 0.226 0.206 0.218 0.196 0.124
Therapeutic Mix 0 0.011 0.069 0.159 0.239 0.324 0.380 0.518 0.621 0.704 0.768 0.816 0.864
Drug Mix 0 0.011 0.018 0.004 -0.013 -0.040 -0.055 -0.060 -0.052 -0.026 -0.049 -0.037 -0.042
Price Changes 0 -0.011 -0.077 -0.262 -0.339 -0.432 -0.464 -0.431 -0.405 -0.385 -0.387 -0.381 -0.376
Product Mix 0 -0.013 -0.031 -0.069 -0.091 -0.065 -0.063 -0.071 -0.082 -0.085 -0.095 -0.087 -0.087
Expenditure per Capita 0 0.122 0.242 0.192 0.262 0.362 0.441 0.704 0.897 1.042 1.122 1.227 1.336
The expenditure per capita in a given year is the sum of the six determinants in the same year
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Euro values of determinants 2003 - 2015 of insulins
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Purchase Volume 0 0.03 0.15 0.34 1.04 1.88 2.47 3.03 3.23 3.38 3.56 3.83 4.30
Purchase Size 0 0.60 1.11 1.51 2.02 2.78 3.48 4.03 4.37 4.51 4.34 4.15 3.98
Therapeutic Mix 0 0.50 0.66 0.82 1.21 1.82 2.42 2.97 3.38 3.61 3.74 3.74 3.74
Drug Mix 0 0.20 0.27 0.37 0.55 0.53 0.56 0.57 0.55 0.46 0.54 0.38 0.38
Price Changes 0 0.09 0.07 -0.21 -0.32 -0.36 -0.39 -0.41 -0.40 -0.50 -0.80 -1.04 -0.95
Product Mix 0 0.02 0.06 -0.14 -0.16 -0.21 -0.29 -0.33 -0.36 -0.41 -0.66 -0.92 -1.07
Expenditure per Capita 0 1.44 2.31 2.69 4.34 6.44 8.25 9.86 10.77 11.05 10.72 10.41 10.38
The expenditure per capita in a given year is the sum of the six determinants in the same year
Euro values of determinants 2003 - 2015 of non-insulins
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Purchase Volume 0 0.49 0.98 1.33 1.89 2.80 3.35 4.31 5.04 5.85 6.52 7.49 9.48
Purchase Size 0 0.20 0.60 0.78 0.94 0.86 0.93 1.43 1.94 1.92 2.12 2.04 1.38
Therapeutic Mix 0 0.06 0.41 0.93 1.44 2.06 2.53 3.98 5.32 6.56 7.50 8.49 9.59
Drug Mix 0 0.06 0.11 0.02 -0.08 -0.25 -0.36 -0.46 -0.45 -0.24 -0.48 -0.38 -0.47
Price Changes 0 -0.06 -0.46 -1.53 -2.05 -2.76 -3.09 -3.31 -3.47 -3.59 -3.78 -3.96 -4.18
Product Mix 0 -0.07 -0.19 -0.40 -0.55 -0.42 -0.42 -0.55 -0.70 -0.79 -0.93 -0.90 -0.97
Expenditure per Capita 0 0.68 1.45 1.13 1.59 2.29 2.59 5.40 7.68 9.71 10.95 12.78 14.83
The expenditure per capita in a given year is the sum of the six determinants in the same year
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